Management of malignant melanoma: best practices

J Cutan Med Surg. 2009 Mar-Apr;13(2):55-73. doi: 10.2310/7750.2008.08029.

Abstract

Background: Melanoma is a commonly occurring cancer in Canada, with an estimated age-standardized incidence of 10 to 13 per 100,000. An estimated 4,300 new cases were diagnosed, and there were 800 reported deaths in 2005.

Objective and conclusion: The Canadian Expert Panel on Malignant Melanoma has developed best practices to improve the management of malignant melanoma. Sections include recommendations on primary diagnosis, dermatopathologic assessment, and reporting; use of preoperative lymphoscintigraphy and an intraoperative gamma probe to map and biopsy the sentinel lymph node; indications for surgical resection, sentinel node biopsy, and surgery for advance disease; use of interferon-alpha adjuvant therapy and treatment options for stage IV disease; and management of central nervous system metastases.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Antineoplastic Agents, Alkylating / therapeutic use
  • Benchmarking
  • Brain Neoplasms / secondary
  • Brain Neoplasms / therapy
  • Combined Modality Therapy
  • Dacarbazine / analogs & derivatives
  • Dacarbazine / therapeutic use
  • Humans
  • Intraoperative Period
  • Melanoma / diagnosis*
  • Melanoma / pathology
  • Melanoma / surgery
  • Melanoma / therapy*
  • Neoplasm Invasiveness
  • Neoplasm Metastasis
  • Prognosis
  • Sentinel Lymph Node Biopsy
  • Skin Neoplasms / diagnosis*
  • Skin Neoplasms / pathology
  • Skin Neoplasms / surgery
  • Skin Neoplasms / therapy*
  • Temozolomide

Substances

  • Antineoplastic Agents, Alkylating
  • Dacarbazine
  • Temozolomide